Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Updated clinical practice guidelines for the treatment and prevention of venous thromboembolism ...
Thromboembol in blood vessel. Clot formation, 3D illustration Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.
This multicenter retrospective cohort study included adult patients with cancer diagnosed with venous thromboembolism (VTE) hospitalized in Thailand from 2017 to 2021. Anticoagulants were classified ...
Madrid, Spain – 30 August 2025: Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE ...
Venous thromboembolism (VTE) is serious condition that begins with a blood clot in a vein – often in the lower leg – that makes its way to the lungs, causing a pulmonary embolism with potentially ...
The main goal of DVT treatment is to stop a blood clot from breaking loose and traveling to the lungs, a condition called pulmonary embolism (PE). This can block blood flow to the lungs and cause ...
If the choice is made to anticoagulate patients with symptomatic isolated distal deep vein thrombosis (DVT), outcomes will be improved with 12 versus 6 weeks of treatment, the randomized, ...
Anybody can develop a deep vein thrombosis (DVT). It's a serious public health issue. But some are more likely to get this clot – or even die from it – than others due to differences in treatment.
A model incorporating C-reactive protein and D-Dimer may be prognostic for bladder cancer-related thrombosis. Combining C-reactive protein (CRP) and D-dimer (D-D) levels may improve prediction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback